drugset / Trial / NCT00549068

POWER Point of Care Effect on Satisfaction of Treatment

NCT00549068

Phase 4 Completed 2433 enrolled Sanofi Procter and Gamble · collab
RandomizedSingle-groupOpen-labelTreatment

Summary

To compare the subject satisfaction rating in women treated for postmenopausal osteoporosis with Actonel 35mg Once-a-Week for 24 weeks, and receiving feedback information, after 12 weeks of treatment, based on bone resorption marker results using the NTx Point-Of-Care (POC) device, to similar women treated as per regular clinical practice

Timeline

Start
2003-02
Primary completion
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Risedronate Small molecule 35 mg